This company has been marked as potentially delisted and may not be actively trading. Aileron Therapeutics (ALRN) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock ALRN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Rodman & Renshaw sets $8 target for Rein Therapeutics stockJanuary 28, 2025 | msn.comAileron Therapeutics Rebrands As Rein TherapeuticsJanuary 10, 2025 | markets.businessinsider.comAileron Therapeutics Announces Rebranding to Rein TherapeuticsJanuary 10, 2025 | prnewswire.comWiechart speaks on Aileron's impact on his small businessJanuary 7, 2025 | yahoo.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Decrease in Short InterestNovember 29, 2024 | marketbeat.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 8.7% in OctoberNovember 17, 2024 | marketbeat.comAileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 14, 2024 | prnewswire.comAileron reports results from Cohort 2 of its Phase 1b clinical trial of LTI-03November 14, 2024 | markets.businessinsider.comAileron Therapeutics Reports Positive Phase 1b Data Of LTI-03 In Idiopathic Pulmonary FibrosisNovember 14, 2024 | markets.businessinsider.comAileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung FibrosisNovember 14, 2024 | finance.yahoo.comAileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)November 13, 2024 | prnewswire.comAileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for RetinoblastomaOctober 31, 2024 | prnewswire.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest UpdateOctober 14, 2024 | marketbeat.comAileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway FibrosisOctober 12, 2024 | prnewswire.comAileron Therapeutics (NASDAQ:ALRN) Stock, Insider Trading ActivityOctober 6, 2024 | benzinga.comUniversity of Texas Texas AM Investment Management Co. Invests $4.93 Million in Aileron Therapeutics, Inc. (NASDAQ:ALRN)October 2, 2024 | marketbeat.comNantahala Capital Management LLC Raises Stock Holdings in Aileron Therapeutics, Inc. (NASDAQ:ALRN)October 1, 2024 | marketbeat.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 13.4% in SeptemberSeptember 28, 2024 | marketbeat.comAileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)September 23, 2024 | prnewswire.comUniversity of Texas Texas AM Investment Management Co. Makes New Investment in Aileron Therapeutics, Inc. (NASDAQ:ALRN)September 3, 2024 | marketbeat.comAileron Therapeutics reports voting results from annual meetingAugust 24, 2024 | investing.comAileron Therapeutics to Present at the 8th Annual IPF SummitAugust 19, 2024 | prnewswire.comAileron Therapeutics, Inc.: Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 15, 2024 | finanznachrichten.deAileron Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 14, 2024 | prnewswire.comAileron Therapeutics Inc (ALRN)August 10, 2024 | investing.comAileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth ConferenceJuly 30, 2024 | prnewswire.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Growth in Short InterestJuly 12, 2024 | marketbeat.comAileron Therapeutics to be Included in the Russell Microcap® IndexJuly 1, 2024 | prnewswire.comShort Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Decreases By 41.3%June 28, 2024 | marketbeat.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Of Texas/Texas Am I. University Sells 4,707 SharesJune 18, 2024 | insidertrades.comOf Texas/Texas Am I. University Sells 9,342 Shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) StockJune 13, 2024 | insidertrades.comInsider Selling: Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells 9,577 Shares of StockJune 13, 2024 | insidertrades.comInsider Selling: Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells 6,291 Shares of StockJune 8, 2024 | insidertrades.comAileron Therapeutics (NASDAQ:ALRN) Rating Increased to Strong-Buy at Brookline Capital ManagementJune 1, 2024 | marketbeat.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Large Increase in Short InterestMay 29, 2024 | marketbeat.comAileron Therapeutics (NASDAQ:ALRN) Releases Earnings Results, Misses Expectations By $0.72 EPSMay 21, 2024 | marketbeat.comAileron Therapeutics, Inc.: Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 16, 2024 | finanznachrichten.deALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024May 15, 2024 | msn.comAileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 15, 2024 | tmcnet.comAileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 15, 2024 | globenewswire.comAileron Therapeutics to Present at Two Upcoming Investor ConferencesMay 6, 2024 | globenewswire.comALRN Aileron Therapeutics, Inc.May 3, 2024 | seekingalpha.comAileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionMay 3, 2024 | finance.yahoo.comAileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionMay 3, 2024 | globenewswire.comAileron reports data from Cohort 1 of Phase Ib inhaled IPF treatment trialMay 2, 2024 | finance.yahoo.comInsider Selling: Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells 10,746 Shares of StockMay 2, 2024 | insidertrades.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells $53,192.70 in StockMay 1, 2024 | marketbeat.comAileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 MillionMay 1, 2024 | globenewswire.comAileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)May 1, 2024 | globenewswire.comShort Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Rises By 22.9%April 28, 2024 | marketbeat.com Get Aileron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALRN Media Mentions By Week ALRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALRN News Sentiment▼0.000.70▲Average Medical News Sentiment ALRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALRN Articles This Week▼01▲ALRN Articles Average Week Get the Latest News and Ratings for ALRN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aileron Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies MediWound News Caribou Biosciences News Monopar Therapeutics News Journey Medical News C4 Therapeutics News Tenaya Therapeutics News Cybin News Ventyx Biosciences News China SXT Pharmaceuticals News FitLife Brands News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALRN) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aileron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
